Continued access to HIV treatment after a parent study
Part of Immune system & allergy, Infections clinical trials.
This study lets people who finished an earlier HIV treatment study keep getting the same medicine while a new trial is set up. It helps ensure you don't have a gap in your treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been in a ViiV Healthcare-sponsored HIV treatment study and completed the planned treatment period.
- Your doctor must confirm that you are still benefiting from the treatment and that you are still eligible for the original study.
- You must be willing to attend all scheduled visits and follow the study plan.
- You must be able to give your permission to join, or have a legally authorized representative do so.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different ways to manage “virologic failure,” meaning HIV viral load stays high while taking TLD (a common HIV medicine combination). It may help people better control the virus and improve treatment results, especially in parts of sub-Saharan Africa.
This program provides access to an investigational HIV medication called fostemsavir for people who have run out of standard options due to drug resistance or intolerance. It aims to help control the virus when other combinations fail.
This is an observational study (not a new drug) that tracks how living with HIV can change over time in different treatment situations. It may help researchers understand long-term effects of the modern “protease inhibitor era” and improve future care.
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
This trial provides continued access to Biktarvy (B/F/TAF) for children and adolescents who completed a previous Gilead HIV study. It ensures they can keep taking the medication without interruption.
This study is for people with HIV who have had a gap in care (missed an appointment or had a detectable viral load). It tests a program to help you stay on your dolutegravir-based HIV medication and keep your viral load undetectable.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.